Medicare GLP-1 Bridge Program: What Medicare Beneficiaries Need to Know

Medicare GLP-1 Bridge Program: Weight Loss Medication Coverage in 2026

Beginning July 1, 2026, the Centers for Medicare & Medicaid Services will launch a new temporary program called the Medicare GLP-1 Bridge Program. The program is designed to help eligible Medicare Part D beneficiaries access certain GLP-1 medications when they are prescribed for weight loss, obesity treatment, or maintaining weight reduction. CMS says the program will run from July 1, 2026 through December 31, 2027.

For many Medicare beneficiaries, this is an important change. Historically, Medicare Part D has generally not covered medications used only for weight loss. Some GLP-1 medications may be covered under Part D when prescribed for certain other medical conditions, such as diabetes or other approved indications, but coverage for obesity alone has been limited. The Medicare GLP-1 Bridge Program is intended to provide temporary access outside of the normal Part D benefit.

What Is the Medicare GLP-1 Bridge Program?

The Medicare GLP-1 Bridge Program is a short-term CMS demonstration program. It is not a Medicare Advantage plan, Medigap plan, or standard Part D plan. Instead, CMS will manage the program separately from a beneficiary’s existing prescription drug coverage.

Under the program, eligible Medicare Part D beneficiaries may be able to access certain GLP-1 medications for a $50 copay for a monthly supply. CMS has stated that the program will operate outside of a beneficiary’s Medicare Part D plan and will use a central processor for prior authorization, claims processing, and pharmacy payment.

This means the program is separate from how your regular Medicare drug plan normally works.

Who May Be Eligible?

Eligibility for the Medicare GLP-1 Bridge Program depends on CMS criteria. Beneficiaries may need to meet requirements related to:

• Age
• Body mass index, or BMI
• A prescription for weight loss or maintaining weight reduction
• Use of the medication along with lifestyle modifications
• Other qualifying health conditions

CMS guidance indicates that the program is designed for beneficiaries seeking GLP-1 medications solely to reduce excess body weight or maintain weight reduction. Certain other GLP-1 uses, including type 2 diabetes, obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis, may be eligible for Part D coverage depending on the plan and medication.

Because eligibility depends on medical criteria, beneficiaries should speak directly with their doctor or healthcare provider to find out whether they may qualify.

How Do I Apply for the Medicare GLP-1 Bridge Program

Beneficiaries do not simply use their regular Part D drug card for the Medicare GLP-1 Bridge Program.

To be considered, the beneficiary should work with their healthcare provider. The provider will need to submit a Medicare GLP-1 Bridge prior authorization request to CMS or the program processor.

If the request is approved, the pharmacy will collect the required $50 copay and submit the claim through the Medicare GLP-1 Bridge processor.

This is an important distinction. If the pharmacy tries to bill the beneficiary’s regular Medicare Part D plan for a medication that is being accessed through the GLP-1 Bridge Program, the claim may reject because the program is separate from Part D coverage.

Does This Change Medicare Part D Coverage?

No. The Medicare GLP-1 Bridge Program does not change your Medicare Part D coverage.

Your Part D plan will still have its own formulary, copays, prior authorization rules, step therapy rules, and coverage requirements. If you use a GLP-1 medication for a condition that may already be covered under Part D, your drug plan may still cover it according to the plan’s rules.

For example, some beneficiaries may use GLP-1 medications for diabetes or another approved medical indication. In those cases, coverage may continue to be handled through the beneficiary’s Part D plan, depending on the medication, diagnosis, and plan formulary.

Beneficiaries should always review their plan’s formulary and Evidence of Coverage to understand how their current drug plan handles GLP-1 medications.

What If You Have a Medicare Advantage Plan With Drug Coverage?

Many Medicare Advantage plans include built-in Part D prescription drug coverage. These are often called MAPD plans.

If you are enrolled in a Medicare Advantage plan with drug coverage, the Medicare GLP-1 Bridge Program is still separate from your plan’s drug benefit.

The program does not replace your Medicare Advantage drug coverage. It also does not expand your plan’s formulary or change your plan’s existing coverage rules.

If your GLP-1 medication is prescribed for a Part D-covered indication, your Medicare Advantage drug plan may still provide coverage according to its formulary and prior authorization requirements. If the medication is being accessed through the Medicare GLP-1 Bridge Program, it would be handled separately.

Do GLP-1 Bridge Program Costs Count Toward Your Part D Out-of-Pocket Maximum?

No. Costs under the Medicare GLP-1 Bridge Program do not count toward your Medicare Part D out-of-pocket maximum.

That is because the program is administered separately from your Part D plan. CMS specifically describes the Medicare GLP-1 Bridge as a demonstration that does not constitute a Medicare Part D plan offering prescription drug coverage.

This matters because beneficiaries may assume that any prescription cost they pay at the pharmacy counts toward their Part D spending. In this case, the $50 GLP-1 Bridge copay is separate from your Part D plan’s normal cost-tracking rules.

Why This Program Matters

The Medicare GLP-1 Bridge Program could be significant for beneficiaries who have struggled to access weight loss medications due to cost or lack of coverage.

GLP-1 medications can be expensive when paid for out of pocket. CMS has described the program as a way to improve access to evidence-based weight-loss treatments for eligible Medicare beneficiaries at a predictable monthly cost.

However, this is not automatic coverage for everyone on Medicare. Beneficiaries must meet CMS eligibility requirements, and a provider must submit the required prior authorization request.

Important Reminder: This Program Is Temporary

The Medicare GLP-1 Bridge Program is a temporary CMS demonstration program. It is currently scheduled to run from July 1, 2026 through December 31, 2027. Because it is a demonstration program, CMS may change, extend, or end the program in the future.

Beneficiaries who are interested in GLP-1 medications for weight loss should speak with their healthcare provider. Your doctor can help determine whether the medication is medically appropriate and whether you may meet the program’s eligibility requirements.

Need Help Understanding Your Medicare Drug Coverage?

Medicare drug coverage can be confusing, especially when a program is separate from your Part D plan.

At Plan Medicare, we help beneficiaries understand their Medicare options, including Medicare Advantage, Medicare Supplement, and Part D prescription drug coverage. While your doctor should guide your medical treatment decisions, we can help you understand how your Medicare plan works and what questions to ask about your prescription drug coverage.

Have questions about your Medicare coverage? Contact Plan Medicare today for help reviewing your options.